Fairness Opinion for Ypsomed

On 22. April 2025, Ypsomed and TecMed AG (TecMed) announced that they had entered into an agreement for the sale of Ypsomed’s diabetes care business for up to CHF 420 million, including earn-out. TecMed is a company based in Burgdorf, controlled by Willy Michel. Ypsomed is focusing on strengthening its leading position in the market for subcutaneous self-injection solutions for pharmaceutical and biotech companies.

‍

Ypsomed is selling Ypsomed Diabetes Care AG, including the relevant subsidiaries, the patch pump development activities and related rights to TecMed. The transaction is expected to close in the second half of 2025, subject to regulatory approvals of the ongoing carve-out. The sale proceeds will finance Ypsomed’s expansion of the injection system business.

‍

Ypsomed is convinced that two specialized companies will be more focused, more agile, and therefore, more successful in the long term.

Support by IFBC

IFBC prepared an independent Fairness Opinion for the Board of Directors of Ypsomed to assess the financial adequacy of the transaction. Based on its analysis and valuation considerations, IFBC considers the sale price for Ypsomed Diabetes Care AG to be fair and reasonable from a financial point of view. IFBC specializes in preparing Fairness Opinions, is a particularly qualified evaluator (accredited by the Takeover Commission pursuant to Art. 30 para. 6 UEV) and is the Swiss market leader in this field. The report has not been published due to competitive and confidential information.

About Ypsomed

Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a proven diabetes specialist. The company has celebrated its 40th anniversary in 2024. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens and autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brand mylife diabetes care directly to patients, pharmacies and hospitals as well as  under Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies. Ypsomed is headquartered in Burgdorf, Switzerland. The company has a global network of production facilities, subsidiaries and distribution partners. Ypsomed has over 2,800 employees worldwide. For further information, please visit ypsomed.ch.

‍